BioRestorative Therapies (BRTX) 10-Q 15 May 19 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 14, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	BioRestorative Therapies, Inc.
Entity Central Index Key	0001505497
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		17,481,068
Trading Symbol	BRTX
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2019

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current Assets:
Cash	$ 496,279	$ 117,523
Accounts receivable	29,000	29,000
Prepaid expenses and other current assets	122,045	34,464
Total Current Assets	647,324	180,987
Property and equipment, net	141,297	175,235
Intangible assets, net	795,334	814,059
Security deposit		22,100
Total Assets	1,583,955	1,192,381
Current Liabilities:
Accounts payable	1,567,556	1,893,827
Accrued expenses and other current liabilities	2,493,867	2,302,176
Accrued interest	402,065	338,619
Current portion of notes payable, net of debt discount of $2,440,769 and $936,866 at March 31, 2019 and December 31, 2018, respectively	3,513,005	3,625,659
Derivative liabilities	751,893	1,094,607
Total Current Liabilities	8,728,386	9,254,888
Accrued expenses, non-current portion		36,500
Accrued interest, non-current portion	20,201	18,137
Notes payable, non-current portion, net of debt discount of $16,394 and $75,497 at March 31, 2019 and December 31, 2018, respectively	488,112	523,894
Total Liabilities	9,236,699	9,833,419
Commitments and contingencies (See Note 6)
Stockholders' Deficiency:
Preferred stock, $0.01 par value; Authorized, 20,000,000 shares; None issued and outstanding at March 31, 2019 and December 31, 2018
Common stock, $0.001 par value; Authorized, 75,000,000 shares; Issued and outstanding 14,732,411 and 11,728,394 shares at March 31, 2019 and December 31, 2018, respectively	14,732	11,728
Additional paid-in capital	60,137,952	55,269,490
Accumulated deficit	(67,805,428)	(63,922,256)
Total Stockholders' Deficiency	(7,652,744)	(8,641,038)
Total Liabilities and Stockholders' Deficiency	$ 1,583,955	$ 1,192,381

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Notes payable current, debt discount	$ 2,440,769	$ 936,866
Notes payable non-current, debt discount	$ 16,394	$ 75,497
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	14,732,411	11,728,394
Common stock, shares outstanding	14,732,411	11,728,394

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Revenues	$ 29,000	$ 19,000
Operating Expenses:
Marketing and promotion	15,837	41,023
Consulting	599,734	432,930
Research and development	455,006	407,130
General and administrative	1,286,759	1,368,655
Total Operating Expenses	2,357,336	2,249,738
Loss From Operations	(2,328,336)	(2,230,738)
Other (Expense) Income:
Interest expense	(316,944)	(161,259)
Amortization of debt discount	(743,142)	(261,646)
Loss on extinguishment of notes payable, net	(448,486)	(18,837)
Change in fair value of derivative liabilities	(46,264)	164,820
Total Other Expense	(1,554,836)	(276,922)
Net Loss	$ (3,883,172)	$ (2,507,660)
Net Loss Per Share
- Basic and Diluted	$ (0.28)	$ (0.39)
Weighted Average Number of Common Shares Outstanding
- Basic and Diluted	13,645,991	6,392,819

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Common Stock [Member]
Balance	$ 11,728	$ 6,112
Balance, shares	11,728,394	6,112,473
Exercise of warrants for purchase of common stock		$ 207
Exercise of warrants for purchase of common stock, shares		207,084
Shares and warrants issued in satisfaction of accrued consulting services	$ 10	$ 19
Shares and warrants issued in satisfaction of accrued consulting services, shares	10,000	19,000
Conversion of notes payable and accrued interest into common stock		$ 27
Conversion of notes payable and accrued interest into common stock, shares		27,018
Shares issued in exchange of notes payable and accrued interest	$ 1,984	$ 85
Shares issued in exchange of notes payable and accrued interest, shares	1,984,017	84,678
Shares issued and recorded as debt discount in connection with note payable issuances or extensions	$ 10	$ 33
Shares issued and recorded as debt discount in connection with note payable issuances or extensions, shares	10,000	33,000
Reclassification of derivative liabilities to equity
Beneficial conversion features related to convertible notes payable
Stock-based compensation: options and warrants
Shares and warrants issued for cash	$ 1,000
Shares and warrants issued for cash, shares	1,000,000
Net loss
Balance	$ 14,732	$ 6,483
Balance, shares	14,732,411	6,483,253
Additional Paid-In Capital [Member]
Balance	$ 55,269,490	$ 44,561,773
Exercise of warrants for purchase of common stock		413,961
Shares and warrants issued in satisfaction of accrued consulting services	7,190	37,981
Conversion of notes payable and accrued interest into common stock		52,877
Shares issued in exchange of notes payable and accrued interest	1,508,298	173,841
Shares issued and recorded as debt discount in connection with note payable issuances or extensions	7,042	61,174
Reclassification of derivative liabilities to equity	2,517,254	9,397
Beneficial conversion features related to convertible notes payable		21,518
Stock-based compensation: options and warrants	729,678	882,812
Shares and warrants issued for cash	99,000
Net loss
Balance	60,137,952	46,215,334
Accumulated Deficit [Member]
Balance	(63,922,256)	(51,404,453)
Exercise of warrants for purchase of common stock
Shares and warrants issued in satisfaction of accrued consulting services
Conversion of notes payable and accrued interest into common stock
Shares issued in exchange of notes payable and accrued interest
Shares issued and recorded as debt discount in connection with note payable issuances or extensions
Reclassification of derivative liabilities to equity
Beneficial conversion features related to convertible notes payable
Stock-based compensation: options and warrants
Shares and warrants issued for cash
Net loss	(3,883,172)	(2,507,660)
Balance	(67,805,428)	(53,912,113)
Balance	(8,641,038)	(6,836,568)
Exercise of warrants for purchase of common stock		414,168
Shares and warrants issued in satisfaction of accrued consulting services	7,200	38,000
Conversion of notes payable and accrued interest into common stock		52,904
Shares issued in exchange of notes payable and accrued interest	1,510,282	173,926
Shares issued and recorded as debt discount in connection with note payable issuances or extensions	7,052	61,207
Reclassification of derivative liabilities to equity	2,517,254	9,397
Beneficial conversion features related to convertible notes payable		21,518
Stock-based compensation: options and warrants	729,678	882,812
Shares and warrants issued for cash	100,000
Net loss	(3,883,172)	(2,507,660)
Balance	$ (7,652,744)	$ (7,690,296)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash Flows From Operating Activities
Net loss	$ (3,883,172)	$ (2,507,660)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	743,142	261,646
Accretion of interest expense	127,743	67,562
Depreciation and amortization	52,663	60,584
Stock-based compensation	785,678	882,812
Loss on extinguishment of note payables, net	263,848	18,837
Gain on settlement of payables	(29,300)
Change in fair value of derivative liabilities	46,264	(164,820)
Changes in operating assets and liabilities:
Accounts receivable		19,000
Prepaid expenses and other current assets	(87,581)	12,685
Security deposit	22,100
Accounts payable	(289,771)	(68,870)
Accrued interest, expenses and other current liabilities	268,224	260,023
Total Adjustments	1,903,010	1,349,459
Net Cash Used In Operating Activities	(1,980,162)	(1,158,201)
Cash Flows From Financing Activities
Proceeds from notes payable	3,073,918	420,500
Repayments of notes payable	(1,315,000)	(119,583)
Proceeds from exercise of warrants		414,168
Sales of common stock and warrants for cash	600,000
Net Cash Provided By Financing Activities	2,358,918	715,085
Net Increase (Decrease) In Cash	378,756	(443,116)
Cash - Beginning	117,523	451,680
Cash - Ending	496,279	8,564
Supplemental Disclosures of Cash Flow Information:
Interest	126,169	9,198
Income tax
Non-cash investing and financing activities:
Shares issued and recorded as debt discount in connection with notes payable issuances or extensions	7,052	61,207
Shares issued in exchange for notes payable and accrued interest	1,510,282	173,926
Conversion of notes payable and accrued interest into common stock		52,904
Shares and warrants issued in satisfaction of accrued consulting services	7,200	38,000
Reclassification of derivative liabilities to equity	2,517,254	9,397
Bifurcated embedded conversion options and warrants recorded as derivative liability and debt discount	2,331,602	235,614
Beneficial conversion features recorded as debt discount		21,518
Warrants issued for consulting services recorded as derivative liabilities	56,000
Accrued interest reclassified to notes payable principal	$ 23,013

Business Organization and Natur

Business Organization and Nature of Operations	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization and Nature of Operations	Note 1 – Business Organization and Nature of Operations BioRestorative Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (“Stem Pearls”). BioRestorative Therapies, Inc. and its subsidiary are referred to collectively as “BRT” or the “Company” (See Note 3 – Summary of Significant Accounting Policies – Principles of Consolidation). BRT develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT’s website is at www.biorestorative.com BRTX-100 The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of March 31, 2019 and for the three months ended March 31, 2019 and 2018. The results of operations for the three months ended March 31, 2019 are not necessarily indicative of the operating results for the full year ending December 31, 2019 or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures of the Company as of December 31, 2018 and for the year then ended, which were filed with the Securities and Exchange Commission on Form 10-K on March 29, 2019.

Going Concern and Management's

Going Concern and Management's Plans	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Management's Plans	Note 2 – Going Concern and Management’s Plans As of March 31, 2019, the Company had a working capital deficiency and a stockholders’ deficiency of $8,081,062 and $7,652,744, respectively. During the three months ended March 31, 2019, the Company incurred a net loss of $3,883,172. These conditions indicate that there is substantial doubt about the Company’s ability to continue as a going concern within the next twelve months from the filing date of this report. The Company’s primary source of operating funds since inception has been equity and debt financings. The Company intends to continue to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis or, notwithstanding any request the Company may make, the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate. The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. Subsequent to March 31, 2019, the Company has received aggregate equity and debt financings of $556,000 and $728,280, respectively, debt (inclusive of accrued interest) of $528,028 has been exchanged for common stock, and $573,400 of debt (inclusive of accrued interest and prepayment premiums) has been repaid. As a result, the Company expects to have the cash required to fund its operations through June 2019 while it continues to apply efforts to raise additional capital. While there can be no assurance that it will be successful, the Company is in negotiations to raise additional capital. As of the filing date of this report, the Company has notes payable with an aggregate principal balance of $190,028 which are past due. The Company is currently in the process of negotiating an extension with respect to these notes though there can be no assurance that the Company will be successful. See Note 9 – Subsequent Events for additional details.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Principles of Consolidation The unaudited condensed consolidated financial statements of the Company include the accounts of Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable, derivative liabilities and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates. Revenue Recognition On January 1, 2019, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” (“ASC 606”). The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The five-step process outlined in the ASC 606 is as follows: Step 1 – Identify the Contract with the Customer – A contract exists when (a) the parties to the contract have approved the contract and are committed to perform their respective obligations, (b) the entity can identify each party’s rights regarding the goods or services to be transferred, (c) the entity can identify the payment terms for the goods or services to be transferred, (d) the contract has commercial substance and it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Step 2 – Identify Performance Obligations in the Contract – Upon execution of a contract, the Company identifies as performance obligations each promise to transfer to the customer either (a) goods or services that are distinct or (b) a series of distinct goods or services that are substantially the same and have the same pattern of transfer to the customer. To the extent a contract includes multiple promised goods or services, the Company must apply judgement to determine whether the goods or services are capable of being distinct within the context of the contract. If these criteria are not met, the goods or services are accounted for as a combined performance obligation. Step 3 – Determine the Transaction Price – When (or as) a performance obligation is satisfied, the Company shall recognize as revenue the amount of the transaction price that is allocated to the performance obligation. The contract terms are used to determine the transaction price. Generally, all contracts include fixed consideration. If a contract did include variable consideration, the Company would determine the amount of variable consideration that should be included in the transaction price based on expected value method. Variable consideration would be included in the transaction price, if in the Company’s judgement, it is probable that a significant future reversal of cumulative revenue under the contract would not occur. Step 4 – Allocate the Transaction Price – After the transaction price has been determined, the next step is to allocate the transaction price to each performance obligation in the contract. If the contract only has one performance obligation, the entire transaction price will be applied to that obligation. If the contract has multiple performance obligations, the transaction price is allocated to the performance obligations based on the relative standalone selling price (SSP) at contract inception. Step 5 – Satisfaction of the Performance Obligations (and Recognize Revenue) – Revenue is recognized when (or as) goods or services are transferred to a customer. The Company satisfies each of its performance obligations by transferring control of the promised good or service underlying that performance obligation to the customer. Control is the ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. It includes the ability to prevent other entities from directing the use of, and obtaining the benefits from, an asset. Indicators that control has passed to the customer include: a present obligation to pay; physical possession of the asset; legal title; risks and rewards of ownership; and acceptance of the asset. Performance obligations can be satisfied at a point in time or over time. The Company recognizes all of its revenue pursuant to a license agreement between the Company and a stem cell treatment company (“SCTC”) entered into in January 2012, as amended in November 2015. Pursuant to the license agreement, the SCTC granted to the Company a license to use certain intellectual property related to, among other things, stem cell disc procedures and the Company has granted to the SCTC a non-exclusive sublicense to use, and the right to sublicense to third parties the right to use, in certain locations in the United States and the Cayman Islands, certain of the licensed intellectual property. In consideration of the sublicenses, the SCTC has agreed to pay the Company royalties on a per disc procedure basis. The Company recognizes sublicensing and royalty revenue on a per disc procedure basis when the third-party sale occurs. All sales have fixed pricing and there are currently no variable components included in the Company’s revenue. The timing of the Company’s revenue recognition may differ from the timing of receiving royalty payments. A receivable is recorded when revenue is recognized prior to receipt of a royalty payment and the Company has an unconditional right to the royalty payment. Alternatively, when a royalty payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied. During the three months ended March 31, 2019 and 2018, the Company recognized $29,000 and $19,000, respectively, of revenue related to the Company’s sublicenses. The Company adopted ASC 606 for all applicable contracts using the modified retrospective method, which would have required a cumulative-effect adjustment, if any, as of the date of adoption. The adoption of ASC 606 did not have a material impact on the Company’s unaudited condensed consolidated financial statements as of the date of adoption. As a result, a cumulative-effect adjustment was not required. Net Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: March 31, 2019 2018 Options 4,750,868 3,615,369 Warrants 4,601,841 3,311,005 Convertible notes 10,747,471 [1] 864,998 Total potentially dilutive shares 20,100,180 7,791,372 [1] As of March 31, 2019, many of the convertible notes had variable conversion prices and the shares were estimated based on market conditions. Pursuant to the note agreements, there were 56,462,559 shares of common stock reserved for future note conversions. Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. The Company estimates the fair value of the awards granted based on the market value of its freely tradable common stock as reported on the OTCQB market. Upon the exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares. Derivative Financial Instruments The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board (“FASB”) ASC. The accounting treatment of derivative financial instruments requires that the Company record embedded conversion options (“ECOs”) and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. Conversion options are recorded as a discount to the host instrument and are amortized as amortization of debt discount on the unaudited condensed consolidated financial statements over the life of the underlying instrument. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. The Multinomial Lattice Model and Black-Scholes Model were used to estimate the fair value of the ECOs of convertible notes payable, warrants and stock options that are classified as derivative liabilities on the unaudited condensed consolidated balance sheets. The models include subjective input assumptions that can materially affect the fair value estimates. The expected volatility is estimated based on the actual volatility during the most recent historical period of time equal to the weighted average life of the instruments. Sequencing Policy Under ASC 815-40-35, the Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares as a result of certain securities with a potentially indeterminable number of shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares. Pursuant to ASC 815, issuance of securities to the Company’s employees or directors are not subject to the sequencing policy. Reclassification Certain amounts in prior periods have been reclassified to conform to the current period presentation. These reclassifications had no effect on previously reported net loss. Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed. Recently Issued Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This amendment will be effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The FASB issued ASU No. 2018-10 “Codification Improvements to Topic 842, Leases” (“ASU 2018-10”), ASU No. 2018-11 “Leases (Topic 842) Targeted Improvements” (“ASU 2018-11”) in July 2018, and ASU No. 2018-20 “Leases (Topic 842) - Narrow Scope Improvements for Lessors” (“ASU 2018-20”) in December 2018. ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating these ASUs and their impact on its unaudited condensed consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments”. The new standard will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2018. The Company has adopted this standard as of January 1, 2019. The adoption of this standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements and financial statement disclosures. In June 2018, the FASB issued ASU No. 2018-07, “Compensation — Stock Compensation (Topic 718)” (“ASU 2018-07”). ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for nonemployee share-based payments. Currently, the accounting requirements for nonemployee and employee share-based payment transactions are significantly different. ASU 2018-07 expands the scope of Topic 718, Compensation — Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity — Equity-Based Payments to Nonemployees. The amendments in this ASU are effective for fiscal years beginning after December 15, 2019 and including interim periods within that fiscal year. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The Company early adopted this accounting standard as of January 1, 2019. The adoption of this standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements and financial statement disclosures. In March 2019, the FASB issued ASU 2019-01, “Leases (Topic 842): Codification Improvements” (“Topic 842”) (“ASU 2019-01”). These amendments align the guidance for fair value of the underlying asset by lessors that are not manufacturers or dealers in Topic 842 with that of existing guidance. As a result, the fair value of the underlying asset at lease commencement is its cost, reflecting any volume or trade discounts that may apply. However, if there has been a significant lapse of time between when the underlying asset is acquired and when the lease commences, the definition of fair value (in Topic 820, Fair Value Measurement) should be applied. (Issue 1). The ASU also requires lessors within the scope of Topic 942, Financial Services—Depository and Lending, to present all “principal payments received under leases” within investing activities. (Issue 2). Finally, the ASU exempts both lessees and lessors from having to provide certain interim disclosures in the fiscal year in which a company adopts the new leases standard. (Issue 3). The transition and effective date provisions apply to Issue 1 and Issue 2. They do not apply to Issue 3 because the amendments for that Issue are to the original transition requirements in Topic 842. The effective date of those amendments is for fiscal years beginning after December 15, 2019. The Company is currently evaluating ASU 2019-01 and its impact on its unaudited condensed consolidated financial statements and financial statement disclosures.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2019
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Note 4 – Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities are comprised of the following: March 31, December 31, 2019 2018 Accrued payroll and other accrued expenses $ 38,934 $ 91,560 Accrued research and development expenses 676,175 646,175 Accrued general and administrative expenses 1,268,499 1,084,831 Accrued director compensation 482,500 482,500 Deferred rent 27,759 33,610 Total accrued expenses 2,493,867 2,338,676 Less: accrued expenses, current portion 2,493,867 2,302,176 Accrued expenses, non-current portion $ - $ 36,500 During the three months ended March 31, 2019, the Company entered into a settlement agreement with a certain consultant, pursuant to which $46,500 of previously accrued consulting fees were exchanged for 10,000 shares of the Company’s common stock and a $10,000 cash payment. The value of the shares was $7,200, and accordingly the Company recorded a gain on settlement of payables of $29,300 which is reflected within general and administrative expenses in the unaudited condensed consolidated statements of operations.

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Notes Payable	Note 5 – Notes Payable A summary of the notes payable activity during the three months ended March 31, 2019 is presented below: Related Party Convertible Other Debt Notes Notes Notes Discount Total Outstanding, January 1, 2019 $ 720,000 $ 4,309,415 $ 132,501 $ (1,012,363 ) $ 4,149,553 Issuances 475,000 2,903,014 [1] - - 3,378,014 Exchanges for equity - (641,649 ) - 121,804 (519,845 ) Repayments (15,000 ) (1,300,000 ) - 51,050 (1,263,950 ) Extinguishment of notes payable - - (148,014) [1] 6,196 (141,818 ) Recognition of debt discount - - - (2,494,735 ) (2,494,735 ) Accretion of interest expense - - - 127,743 127,743 Accrued interest reclassified to notes payable principal - - 23,013 - 23,013 Amortization of debt discount - - - 743,142 743,142 Outstanding, March 31, 2019 [2] $ 1,180,000 $ 5,270,780 [3] $ 7,500 $ (2,457,163 ) $ 4,001,117 [1] During the three months ended March 31, 2019, a convertible note in the principal amount of $148,014 was issued concurrently with the extinguishment of a certain note payable in the same aggregate principal amount. See below within Note 5 – Notes Payable – Conversions, Exchanges and Other for additional details. [2] As of March 31, 2019, outstanding related party notes, convertible notes and other notes in the aggregate principal amount of $0, $127,742 and $7,500, respectively, were considered past due. [3] As of March 31, 2019, a portion of convertible notes with an aggregate principal balance of $3,465,780 were convertible into shares of common stock at the election of the holder any time until the balance has been paid in full. As of March 31, 2019, a portion of convertible notes with an aggregate principal balance of $1,805,000, which are not currently convertible, will become convertible into shares of the Company’s common stock at the election of the respective holder subsequent to March 31, 2019. Related Party Notes During the three months ended March 31, 2019, the Company issued to family members of an officer of the Company and a Scientific Advisory Board member (the “SAB Member”) notes payable in the aggregate principal amount of $475,000, which bear interest at the rate of 15% per annum and provide for maturity dates between July 2019 and August 2019. During the three months ended March 31, 2019, the Company partially repaid a certain related party note in the principal amount of $15,000. During the three months ended March 31, 2019, the Company and a certain related party agreed to further extend the maturity date of a note payable with a principal balance of $30,000 from January 2019 to December 2019. As of March 31, 2019, related party notes consisted of notes payable issued to certain directors of the Company, family members of an officer of the Company, the SAB Member, and the Tuxis Trust (the “Trust”). A director and principal shareholder of the Company serves as a trustee of Trust, which was established for the benefit of his immediate family. As of March 31, 2019, certain related party notes in the aggregate principal amount of $475,000 were convertible into shares of common stock of the Company at a conversion price of $0.60 per share, subject to adjustment, and a five year warrant (the “Warrant”) for the purchase of a number of shares equal to the number of shares issued upon the conversion of the principal amount of the Note. The Warrant provides for an exercise price of $0.80 per share, subject to adjustment. The other related party notes in the aggregate principal amount of $705,000 were not convertible. Convertible Notes Issuances During the three months ended March 31, 2019, the Company issued to certain lenders convertible notes payable in the aggregate principal amount of $2,755,000 for aggregate cash proceeds of $2,598,918. The difference of $156,083 was recorded as original issuance debt discount and will be amortized over the terms of the respective notes. The convertible notes bear interest at rates ranging between 8% and 15% per annum payable at maturity with original maturity dates ranging between July 2019 and March 2020. In connection with the issuance of a certain convertible note, the Company issued the lender a five-year warrant to purchase 40,000 shares of the Company’s common stock at an exercise price of $1.00 per share. The grant date value of the warrant was $24,000, which was recorded as debt discount and is being amortized over the term of the convertible note. The warrant was subject to the Company’s sequencing policy and, as a result, was recorded as a derivative liability. See below within Note 5 – Notes Payable – Conversions, Exchanges and Other and Note 8 – Derivative Liabilities for additional details regarding the ECOs of the convertible notes. During the three months ended March 31, 2019, a certain convertible note in the principal amount of $148,014 was issued concurrently with the extinguishment of a certain other note payable in the same principal amount. See below within Note 5 – Notes Payable – Convertible Notes – Conversions, Exchanges and Other for additional details. Embedded Conversion Options and Note Provisions As of March 31, 2019, outstanding convertible notes in the aggregate principal amount of $3,465,780 were convertible into shares of common stock of the Company as follows: (i) $1,890,000 of aggregate convertible notes were convertible at a fixed price ranging from $1.00 to $2.00 per share for the first six months following the respective issue date, and thereafter at a conversion price generally equal to a range of 58% to 65% of the fair value of the Company’s stock, subject to adjustment, until the respective note has been paid in full, (ii) $50,000 of convertible notes were convertible at a fixed conversion price of $2.15 per share, (iii) $875,780 of aggregate convertible notes were convertible generally at a range of 58% to 65% of the fair value of the Company’s stock, subject to adjustment, depending on the note, and (iv) $650,000 of aggregate convertible notes were convertible into shares of common stock of the Company at a conversion price of $0.60 per share, subject to adjustment, and a five year warrant (the “Warrant”) for the purchase of a number of shares equal to the number of shares issued upon the conversion of the principal amount of the respective note. The Warrant provides for an exercise price of $0.80 per share, subject to adjustment. The Company analyzes the ECOs of its convertible notes at issuance to determine whether the ECO should be bifurcated and accounted for as a derivative liability or if the ECO contains a beneficial conversion feature. See below within Note 5 – Notes Payable – Convertible Notes – Embedded Conversion Options and Note Provisions and Note 8 – Derivative Liabilities for additional details regarding the ECOs of the convertible notes. As of March 31, 2019, a portion of convertible notes with an aggregate principal balance of $1,805,000, which were not yet convertible, will generally become convertible into shares of the Company’s common stock subsequent to March 31, 2019 at a conversion price generally equal to 58% of the fair value of the Company’s stock, subject to adjustment, until the respective notes have been paid in full. As of March 31, 2019, a certain outstanding convertible note in the principal amount of $55,000 has mandatory prepayment terms at the option of the holder (“MPOs”). The MPOs permit the holder to demand prepayment of the note, in cash, at a premium of 35% of the then outstanding principal balance and accrued interest during the period between 150 days to 179 days following the issuance date. As of the date of this filing, the MPOs have expired. As of March 31, 2019, outstanding convertible notes in the aggregate principal amount of $3,953,014 have prepayment premiums, whereby, in the event that the Company elects to prepay certain notes during the first ninety-day period following the issue date, the respective holder is entitled to receive a prepayment premium of up to 30%, depending on the note, on the then outstanding principal balance including accrued interest. In the event that the Company prepays any of the notes during the second ninety-day period following the issue date, the respective holder is entitled to receive a prepayment premium of up to 40%, depending on the note, on the then outstanding principal balance including accrued interest. As of March 31, 2019, outstanding convertible notes in the aggregate principal amount of $2,052,742 have most favored nation (“MFN”) provisions, whereby, so long as such respective note is outstanding, upon any issuance by the Company of any security with certain identified provisions more favorable to the holder of such security, then at the respective holder’s option, those more favorable terms shall become a part of the transaction documents with the holder. As of March 31, 2019, notes with applicable MFN provisions were convertible using MFN conversion prices equal to 58% or 65% of the fair market value of the Company’s stock, as defined. During the three months ended March 31, 2019, the Company determined that certain ECOs of issued or extended convertible notes were derivative liabilities. The aggregate issuance date value of the bifurcated ECOs was $2,392,400, of which $2,307,602 was recorded as a debt discount and is being amortized over the terms of the respective convertible notes and $84,798 was recognized as part of an extinguishment loss as described below. See Note 8 – Derivative Liabilities for additional details. Conversions, Exchanges and Other During the three months ended March 31, 2019, the Company and certain lenders exchanged certain convertible notes with bifurcated ECOs with an aggregate net carrying amount of $1,388,477 (including an aggregate of $641,649 of principal less debt discount of $121,804, $24,509 of accrued interest and $844,123 related to the separated ECOs accounted for as derivative liabilities) for an aggregate of 1,984,017 shares of the Company’s common stock at conversion prices ranging from $0.28 to $0.42 per share. The common stock had an aggregate exchange date value of $1,510,282 and, as a result, the Company recorded a loss on extinguishment of notes payable of $121,805. See Note 8 – Derivative Liabilities for additional details. During the three months ended March 31, 2019, the Company repaid an aggregate principal amount of $1,300,000 of convertible notes payable, $76,169 of the respective aggregate accrued interest and an aggregate of $184,637 of prepayment premiums. As a result of the repayments, the Company recorded a loss on extinguishment of notes payable of $235,687 and an aggregate of $51,050 of the related debt discounts were extinguished. During the three months ended March 31, 2019, a certain lender to the Company acquired a promissory note (classified in Other Notes) issued by the Company in the outstanding amount of $148,014 (inclusive of accrued interest reclassified to principal of $23,013) from a certain lender to the Company. The Company exchanged the acquired note for a new convertible note in the principal amount of $148,014 which accrues interest at a rate of 12% per annum, payable on the maturity date in March 2020. The ECO of the note was subject to sequencing and the issuance date fair value of $84,798 was accounted for as a derivative liability (see Note 8 – Derivative Liabilities for additional details). Since the fair value of the new ECO exceeded 10% of the principal amount of the new note, the note exchange was accounted for as an extinguishment, and accordingly the Company recognized a net loss on extinguishment of $90,994 in connection with the derecognition of the net carrying amount of $141,818 of the extinguished debt and the issuance of the new convertible notes in the aggregate principal amount $148,014 plus the fair value of the new note’s ECO of an aggregate of $84,798. Other Notes Exchange and Other During the three months ended March 31, 2019, the Company and a certain lender agreed to an extension of the maturity date of a certain note payable with a principal balance of $125,000 from a maturity date in January 2019 to a new maturity date in December 2019. In consideration of the extension, the Company issued the lender 10,000 shares of the Company’s common stock. The issuance date fair value of the common stock of $7,052 was recorded as debt discount and is being amortized over the remaining term of the note. During the three months ended March 31, 2019, a convertible promissory note in the principal amount of $148,014 was issued concurrently with the extinguishment of a certain other note payable in the same principal amount. See above within Note 5 – Notes Payable – Conversions, Exchanges and Other for additional details.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6 – Commitments and Contingencies Consulting Agreements Business Advisory Services In January 2019, an agreement for business advisory services that had expired on December 31, 2018 was further extended and now provides for an expiration date of December 31, 2019. In consideration of the extension of the term of the consulting agreement, the Company issued to the consultant a five-year, immediately vested warrant for the purchase of 100,000 shares of the Company’s common stock at an exercise price of $1.00 per share. The grant date value of the warrant of $56,000 was recognized immediately as stock-based compensation expense which is reflected as consulting expense in the unaudited condensed consolidated financial statements. The warrant was subject to the Company’s sequencing policy and, as a result, was recorded as a derivative liability. See Note 8 – Derivative Liabilities for additional details. Operating Lease Rent expense amounted to approximately $30,000 and $31,000 for the three months ended March 31, 2019 and 2018, respectively. Litigations, Claims and Assessments As of March 31, 2019, the Company was not involved in any legal proceedings, claims or assessments arising from the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. Employment Agreements As of March 31, 2019 and December 31, 2018, the Company had remaining accruals of approximately $9,000 and $91,000, respectively, for bonus milestones which were achieved in prior years and remain unpaid. Subsequent to March 31, 2019, the Company’s Compensation Committee and Board of Directors approved performance goals associated with cash bonuses payable to certain officers for the year ended December 31, 2019 and, as a result, the Company accrued approximately $30,305 for 2019 bonuses as of March 31, 2019. See Note 9 – Subsequent Events for additional details.

Stockholders' Deficiency

Stockholders' Deficiency	3 Months Ended
	Mar. 31, 2019
Stockholders' Equity Note [Abstract]
Stockholders' Deficiency	Note 7 – Stockholders’ Deficiency Authorized Capital and 2010 Equity Plan On March 25, 2019, the Board of Directors of the Company approved an increase in the number of authorized shares of common stock to 150,000,000, subject to shareholder approval. Additionally, the Board of Directors approved an increase in the number of authorized shares issuable under the Company’s 2010 Equity Participation Plan to 20,000,000, subject to shareholder approval. On March 25, 2019, the Board of Directors determined to submit to the Company’s shareholders for their approval amendments to the Certificate of Incorporation of the Company (with the Board of Directors having the authority to select and file one such amendment) to effect a reverse split of the Company’s common stock at a ratio of not less than 1-for-2 and not more than 1-for-20, with the Board of Directors having the discretion as to whether or not the reverse stock split is to be effected, and with the exact ratio of any reverse stock split to be set at a whole number within the above range as determined by the Board of Directors in its discretion. Concurrently, the Board of Directors determined to submit to the Company’s shareholders for their approval a proposal to authorize the Board of Directors, in the event the reverse stock split proposal is approved by the shareholders, in its discretion, to reduce the number of authorized shares of common stock in proportion to the percentage decrease in the number of outstanding shares of common stock resulting from the reverse split (or a lesser decrease in authorized shares of common stock as determined by the Board of Directors in its discretion). Warrant and Option Valuation The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. The Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. Common Stock and Warrant Offering During the three months ended March 31, 2019, the Company issued 1,000,000 shares of common stock of the Company, a five-year immediately vested warrant to purchase 500,000 shares of common stock of the Company at an exercise price of $0.85 per share and a one-year immediately vested warrant to purchase 500,000 shares of common stock of the Company at an exercise price of $0.70 per share to an investor for gross proceeds of $600,000. The warrants had an aggregate grant date fair value of $500,000. The warrants were subject to the Company’s sequencing policy and, as a result, were recorded as derivative liabilities. See Note 8 – Derivative Liabilities for additional details. Stock Warrants Warrant Compensation See Note 6 - Commitments and Contingencies for additional details associated with the issuance of a warrant in connection with a consulting agreement extension. The Company recorded stock–based compensation expense of $56,000 and $48,192 during the three months ended March 31, 2019 and 2018, respectively, related to stock warrants issued as compensation, which is reflected as consulting expense in the unaudited condensed consolidated statements of operations. As of March 31, 2019, there was no unrecognized stock-based compensation expense related to stock warrants. Warrant Activity Summary In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: For the Three Months Ended March 31, 2019 2018 Risk free interest rate 2.47% - 2.62 % 1.92% - 2.29 % Contractual term (years) 1.00 - 5.00 1.98 - 5.00 Expected volatility 140% - 150 % 128% - 129 % Expected dividends 0.00 % 0.00 % The weighted average estimated fair value of the warrants granted during the three months ended March 31, 2019 and 2018 was approximately $0.51 and $1.22 per share, respectively. A summary of the warrant activity during the three months ended March 31, 2019 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, January 1, 2019 3,483,403 $ 3.63 Issued 1,140,000 0.80 Expired (21,562 ) 4.80 Outstanding, March 31, 2019 4,601,841 $ 2.92 2.2 $ 45,000 Exercisable, March 31, 2019 4,601,841 $ 2.92 2.2 $ 45,000 The following table presents information related to stock warrants at March 31, 2019: Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $0.70 - $0.99 1,140,000 3.1 1,140,000 $1.00 - $1.99 844,444 0.8 844,444 $2.00 - $2.99 75,000 4.6 75,000 $3.00 - $3.99 70,000 4.3 70,000 $4.00 - $4.99 2,159,635 2.2 2,159,635 $5.00 - $5.99 195,989 2.2 195,989 $6.00 - $7.99 40,000 1.3 40,000 $8.00 - $9.99 2,500 0.7 2,500 $10.00 - $14.99 40,400 1.0 40,400 $15.00 - $19.99 33,873 0.4 33,873 4,601,841 2.2 4,601,841 Stock Options In March 2019, the Board of Directors reduced the exercise price of outstanding stock options for the purchase of an aggregate of 4,631,700 shares of common stock of the Company (with exercise prices ranging between $1.00 and $4.70 per share) to $0.75 per share, which was the closing price for the Company’s common stock on the day prior to determination, as reported by the OTCQB market. The exercise price reduction related to options held by, among others, the Company’s directors, advisors and employees. The incremental value of the modified options compared to the original options, both valued as of the respective modification date, of $452,637 is being recognized over the vesting term of the options. The following table presents information related to stock options at March 31, 2019: Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $0.75 - $0.99 4,631,700 7.1 2,838,709 $1.00 - $5.99 46,668 1.0 46,668 $6.00 - $19.99 37,500 4.8 37,500 $20.00 - $30.00 35,000 3.0 35,000 4,750,868 6.9 2,957,877 The following table presents information related to stock option expense: Weighted Average For the Three Months Ended Unrecognized at Remaining Amortization March 31, March 31, Period 2019 2018 2019 (Years) Consulting $ 296,081 $ 264,227 $ 356,980 0.4 Research and development 149,794 75,845 494,727 1.3 General and administrative 283,802 494,548 819,204 0.8 $ 729,677 $ 834,620 $ 1,670,911 0.9

Derivative Liabilities

Derivative Liabilities	3 Months Ended
	Mar. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	Note 8 – Derivative Liabilities The following table sets forth a summary of the changes in the fair value of Level 3 derivative liabilities that are measured at fair value on a recurring basis: Beginning balance as of January 1, 2019 $ 1,094,607 Issuance of derivative liabilities 2,972,400 Extinguishment of derivative liabilities in connection with convertible note repayments and exchanges (844,124 ) Change in fair value of derivative liabilities 46,264 Reclassification of derivative liabilities to equity (2,517,254 ) Ending balance as of March 31, 2019 $ 751,893 In applying the Multinomial Lattice and Black-Scholes option pricing models to derivatives issued and outstanding during the three months ended March 31, 2019 and 2018, the Company used the following assumptions: For the Three Months Ended March 31, 2019 2018 Risk free interest rate 2.21% - 2.62 % 1.22% - 2.56 % Expected term (years) 0.07 - 5.00 0.75 - 4.66 Expected volatility 104% - 156 % 100% - 111 % Expected dividends 0.00 % 0.00 % During the three months ended March 31, 2019, the Company recorded new derivative liabilities in the aggregate amounts of $2,392,400 and $580,000 related to the ECOs of certain convertible notes payable and warrants subject to sequencing, respectively. See Note 5 – Notes Payable – Convertible Notes for additional details. See Note 6 – Commitments and Contingencies and Note 7 – Stockholders’ Deficiency for warrants issued and deemed to be derivative liabilities. During the three months ended March 31, 2019, the Company extinguished an aggregate of $844,124 of derivative liabilities in connection with repayments and exchanges of certain convertible notes payable into shares of the Company’s common stock. See Note 7 – Notes Payable – Convertible Notes for additional details. During the three months ended March 31, 2019, the Company reclassified an aggregate of $2,517,254 of derivative liabilities to equity as a result of a change in the sequencing status. On March 31, 2019, the Company recomputed the fair value of ECOs recorded as derivative liabilities to be $724,634. The Company recorded a loss on the change in fair value of these derivative liabilities of $96,838 for the three months ended March 31, 2019. On March 31, 2019, the Company recomputed the fair value of the derivative liabilities related to outstanding warrants to be $27,260. These warrants are either redeemable for cash equal to the Black-Scholes value, as defined, at the election of the warrant holder upon a fundamental transaction pursuant to the warrant terms or were issued subsequent to the commencement of sequencing. The Company recorded a gain on the change in fair value of these derivative liabilities of $50,574 for the three months ended March 31, 2019.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 9 – Subsequent Events Common Stock and Warrant Offerings Subsequent to March 31, 2019, the Company issued 80,000 shares of common stock of the Company to an SAB Member at a purchase price of $0.70 per share. In consideration thereof, the Company issued an immediately vested five-year warrant for the purchase of 80,000 shares of common stock of the Company at an exercise price of $1.00 per share. Subsequent to March 31, 2019, the Company issued 1,111,111 shares of common stock of the Company to a certain related party at a purchase price of $0.45 per share. In consideration thereof, the Company issued an immediately vested five-year warrant for the purchase of 555,556 shares of common stock of the Company at an exercise price of $0.85 per share, and an immediately vested one-year warrant for the purchase of 555,555 shares of common stock of the Company at an exercise price of $0.70 per share. Notes Payable Subsequent to March 31, 2019, the Company issued convertible promissory notes in the aggregate principal amount of $760,000 to certain lenders for aggregate cash proceeds of $728,280. The difference of $31,720 was recorded as a debt discount and will be amortized over the terms of the respective notes. The convertible notes bear interest at the rate of 12% per annum, payable at maturity, with original maturity dates ranging from October 2019 to January 2020. The convertible notes and the respective accrued interest are convertible into shares of the Company’s common stock at the election of the holder after the 180th day following the issue date at a conversion price generally equal to 58% of the fair value of the Company’s common stock. In connection with the issuance of a certain convertible promissory note, the Company issued to the lender 68,873 shares of the Company’s common stock. The relative fair value of the common stock will be recorded as a debt discount and will be amortized over the term of the note. In the event that the Company elects to prepay any of the respective notes during the first ninety-day period following the issue date, the holder is entitled to receive a prepayment premium of up to 25%, depending on the note, of the then outstanding principal balance plus accrued interest. In the event that the Company elects to prepay any of the notes during the second ninety-day period following the issue date, the holder is entitled to receive a prepayment premium of up to 35%, depending on the note, of the then outstanding principal balance plus accrued interest. Subsequent to March 31, 2019, the Company and certain lenders agreed to exchange an aggregate principal amount of $504,501 and aggregate accrued interest of $23,527 of certain convertible notes payable for an aggregate of 1,488,673 shares of the Company’s common stock at exchange prices ranging from $0.20 to $0.43 per share. Subsequent to March 31, 2019, the Company repaid an aggregate principal amount of $501,629 of convertible notes payable, $29,371 of the respective aggregate accrued interest and an aggregate of $42,400 of prepayment premiums.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements of the Company include the accounts of Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable, derivative liabilities and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
Revenue Recognition	Revenue Recognition On January 1, 2019, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” (“ASC 606”). The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The five-step process outlined in the ASC 606 is as follows: Step 1 – Identify the Contract with the Customer – A contract exists when (a) the parties to the contract have approved the contract and are committed to perform their respective obligations, (b) the entity can identify each party’s rights regarding the goods or services to be transferred, (c) the entity can identify the payment terms for the goods or services to be transferred, (d) the contract has commercial substance and it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Step 2 – Identify Performance Obligations in the Contract – Upon execution of a contract, the Company identifies as performance obligations each promise to transfer to the customer either (a) goods or services that are distinct or (b) a series of distinct goods or services that are substantially the same and have the same pattern of transfer to the customer. To the extent a contract includes multiple promised goods or services, the Company must apply judgement to determine whether the goods or services are capable of being distinct within the context of the contract. If these criteria are not met, the goods or services are accounted for as a combined performance obligation. Step 3 – Determine the Transaction Price – When (or as) a performance obligation is satisfied, the Company shall recognize as revenue the amount of the transaction price that is allocated to the performance obligation. The contract terms are used to determine the transaction price. Generally, all contracts include fixed consideration. If a contract did include variable consideration, the Company would determine the amount of variable consideration that should be included in the transaction price based on expected value method. Variable consideration would be included in the transaction price, if in the Company’s judgement, it is probable that a significant future reversal of cumulative revenue under the contract would not occur. Step 4 – Allocate the Transaction Price – After the transaction price has been determined, the next step is to allocate the transaction price to each performance obligation in the contract. If the contract only has one performance obligation, the entire transaction price will be applied to that obligation. If the contract has multiple performance obligations, the transaction price is allocated to the performance obligations based on the relative standalone selling price (SSP) at contract inception. Step 5 – Satisfaction of the Performance Obligations (and Recognize Revenue) – Revenue is recognized when (or as) goods or services are transferred to a customer. The Company satisfies each of its performance obligations by transferring control of the promised good or service underlying that performance obligation to the customer. Control is the ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. It includes the ability to prevent other entities from directing the use of, and obtaining the benefits from, an asset. Indicators that control has passed to the customer include: a present obligation to pay; physical possession of the asset; legal title; risks and rewards of ownership; and acceptance of the asset. Performance obligations can be satisfied at a point in time or over time. The Company recognizes all of its revenue pursuant to a license agreement between the Company and a stem cell treatment company (“SCTC”) entered into in January 2012, as amended in November 2015. Pursuant to the license agreement, the SCTC granted to the Company a license to use certain intellectual property related to, among other things, stem cell disc procedures and the Company has granted to the SCTC a non-exclusive sublicense to use, and the right to sublicense to third parties the right to use, in certain locations in the United States and the Cayman Islands, certain of the licensed intellectual property. In consideration of the sublicenses, the SCTC has agreed to pay the Company royalties on a per disc procedure basis. The Company recognizes sublicensing and royalty revenue on a per disc procedure basis when the third-party sale occurs. All sales have fixed pricing and there are currently no variable components included in the Company’s revenue. The timing of the Company’s revenue recognition may differ from the timing of receiving royalty payments. A receivable is recorded when revenue is recognized prior to receipt of a royalty payment and the Company has an unconditional right to the royalty payment. Alternatively, when a royalty payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied. During the three months ended March 31, 2019 and 2018, the Company recognized $29,000 and $19,000, respectively, of revenue related to the Company’s sublicenses. The Company adopted ASC 606 for all applicable contracts using the modified retrospective method, which would have required a cumulative-effect adjustment, if any, as of the date of adoption. The adoption of ASC 606 did not have a material impact on the Company’s unaudited condensed consolidated financial statements as of the date of adoption. As a result, a cumulative-effect adjustment was not required.
Net Loss Per Common Share	Net Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: March 31, 2019 2018 Options 4,750,868 3,615,369 Warrants 4,601,841 3,311,005 Convertible notes 10,747,471 [1] 864,998 Total potentially dilutive shares 20,100,180 7,791,372 [1] As of March 31, 2019, many of the convertible notes had variable conversion prices and the shares were estimated based on market conditions. Pursuant to the note agreements, there were 56,462,559 shares of common stock reserved for future note conversions.
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. The Company estimates the fair value of the awards granted based on the market value of its freely tradable common stock as reported on the OTCQB market. Upon the exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares.
Derivative Financial Instruments	Derivative Financial Instruments The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board (“FASB”) ASC. The accounting treatment of derivative financial instruments requires that the Company record embedded conversion options (“ECOs”) and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. Conversion options are recorded as a discount to the host instrument and are amortized as amortization of debt discount on the unaudited condensed consolidated financial statements over the life of the underlying instrument. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. The Multinomial Lattice Model and Black-Scholes Model were used to estimate the fair value of the ECOs of convertible notes payable, warrants and stock options that are classified as derivative liabilities on the unaudited condensed consolidated balance sheets. The models include subjective input assumptions that can materially affect the fair value estimates. The expected volatility is estimated based on the actual volatility during the most recent historical period of time equal to the weighted average life of the instruments.
Sequencing Policy	Sequencing Policy Under ASC 815-40-35, the Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares as a result of certain securities with a potentially indeterminable number of shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares. Pursuant to ASC 815, issuance of securities to the Company’s employees or directors are not subject to the sequencing policy.
Reclassification	Reclassification Certain amounts in prior periods have been reclassified to conform to the current period presentation. These reclassifications had no effect on previously reported net loss.
Subsequent Events	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This amendment will be effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The FASB issued ASU No. 2018-10 “Codification Improvements to Topic 842, Leases” (“ASU 2018-10”), ASU No. 2018-11 “Leases (Topic 842) Targeted Improvements” (“ASU 2018-11”) in July 2018, and ASU No. 2018-20 “Leases (Topic 842) - Narrow Scope Improvements for Lessors” (“ASU 2018-20”) in December 2018. ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating these ASUs and their impact on its unaudited condensed consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments”. The new standard will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2018. The Company has adopted this standard as of January 1, 2019. The adoption of this standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements and financial statement disclosures. In June 2018, the FASB issued ASU No. 2018-07, “Compensation — Stock Compensation (Topic 718)” (“ASU 2018-07”). ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for nonemployee share-based payments. Currently, the accounting requirements for nonemployee and employee share-based payment transactions are significantly different. ASU 2018-07 expands the scope of Topic 718, Compensation — Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity — Equity-Based Payments to Nonemployees. The amendments in this ASU are effective for fiscal years beginning after December 15, 2019 and including interim periods within that fiscal year. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The Company early adopted this accounting standard as of January 1, 2019. The adoption of this standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements and financial statement disclosures. In March 2019, the FASB issued ASU 2019-01, “Leases (Topic 842): Codification Improvements” (“Topic 842”) (“ASU 2019-01”). These amendments align the guidance for fair value of the underlying asset by lessors that are not manufacturers or dealers in Topic 842 with that of existing guidance. As a result, the fair value of the underlying asset at lease commencement is its cost, reflecting any volume or trade discounts that may apply. However, if there has been a significant lapse of time between when the underlying asset is acquired and when the lease commences, the definition of fair value (in Topic 820, Fair Value Measurement) should be applied. (Issue 1). The ASU also requires lessors within the scope of Topic 942, Financial Services—Depository and Lending, to present all “principal payments received under leases” within investing activities. (Issue 2). Finally, the ASU exempts both lessees and lessors from having to provide certain interim disclosures in the fiscal year in which a company adopts the new leases standard. (Issue 3). The transition and effective date provisions apply to Issue 1 and Issue 2. They do not apply to Issue 3 because the amendments for that Issue are to the original transition requirements in Topic 842. The effective date of those amendments is for fiscal years beginning after December 15, 2019. The Company is currently evaluating ASU 2019-01 and its impact on its unaudited condensed consolidated financial statements and financial statement disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Schedule of Weighted Average Dilutive Common Shares	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: March 31, 2019 2018 Options 4,750,868 3,615,369 Warrants 4,601,841 3,311,005 Convertible notes 10,747,471 [1] 864,998 Total potentially dilutive shares 20,100,180 7,791,372 [1] As of March 31, 2019, many of the convertible notes had variable conversion prices and the shares were estimated based on market conditions. Pursuant to the note agreements, there were 56,462,559 shares of common stock reserved for future note conversions.

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2019
Accrued Liabilities and Other Liabilities [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities are comprised of the following: March 31, December 31, 2019 2018 Accrued payroll and other accrued expenses $ 38,934 $ 91,560 Accrued research and development expenses 676,175 646,175 Accrued general and administrative expenses 1,268,499 1,084,831 Accrued director compensation 482,500 482,500 Deferred rent 27,759 33,610 Total accrued expenses 2,493,867 2,338,676 Less: accrued expenses, current portion 2,493,867 2,302,176 Accrued expenses, non-current portion $ - $ 36,500

Notes Payable (Tables)

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Schedule of Notes Payable Activity	A summary of the notes payable activity during the three months ended March 31, 2019 is presented below: Related Party Convertible Other Debt Notes Notes Notes Discount Total Outstanding, January 1, 2019 $ 720,000 $ 4,309,415 $ 132,501 $ (1,012,363 ) $ 4,149,553 Issuances 475,000 2,903,014 [1] - - 3,378,014 Exchanges for equity - (641,649 ) - 121,804 (519,845 ) Repayments (15,000 ) (1,300,000 ) - 51,050 (1,263,950 ) Extinguishment of notes payable - - (148,014) [1] 6,196 (141,818 ) Recognition of debt discount - - - (2,494,735 ) (2,494,735 ) Accretion of interest expense - - - 127,743 127,743 Accrued interest reclassified to notes payable principal - - 23,013 - 23,013 Amortization of debt discount - - - 743,142 743,142 Outstanding, March 31, 2019 [2] $ 1,180,000 $ 5,270,780 [3] $ 7,500 $ (2,457,163 ) $ 4,001,117 [1] During the three months ended March 31, 2019, a convertible note in the principal amount of $148,014 was issued concurrently with the extinguishment of a certain note payable in the same aggregate principal amount. See below within Note 5 – Notes Payable – Conversions, Exchanges and Other for additional details. [2] As of March 31, 2019, outstanding related party notes, convertible notes and other notes in the aggregate principal amount of $0, $127,742 and $7,500, respectively, were considered past due. [3] As of March 31, 2019, a portion of convertible notes with an aggregate principal balance of $3,465,780 were convertible into shares of common stock at the election of the holder any time until the balance has been paid in full. As of March 31, 2019, a portion of convertible notes with an aggregate principal balance of $1,805,000, which are not currently convertible, will become convertible into shares of the Company’s common stock at the election of the respective holder subsequent to March 31, 2019.

Stockholders' Deficiency (Table

Stockholders' Deficiency (Tables)	3 Months Ended
	Mar. 31, 2019
Stockholders' Equity Note [Abstract]
Schedule of Share Based Payment Award Stock Option Granted Assumptions	In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: For the Three Months Ended March 31, 2019 2018 Risk free interest rate 2.47% - 2.62 % 1.92% - 2.29 % Contractual term (years) 1.00 - 5.00 1.98 - 5.00 Expected volatility 140% - 150 % 128% - 129 % Expected dividends 0.00 % 0.00 %
Schedule of Warrant Activity	A summary of the warrant activity during the three months ended March 31, 2019 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, January 1, 2019 3,483,403 $ 3.63 Issued 1,140,000 0.80 Expired (21,562 ) 4.80 Outstanding, March 31, 2019 4,601,841 $ 2.92 2.2 $ 45,000 Exercisable, March 31, 2019 4,601,841 $ 2.92 2.2 $ 45,000
Schedule of Stock Warrant	The following table presents information related to stock warrants at March 31, 2019: Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $0.70 - $0.99 1,140,000 3.1 1,140,000 $1.00 - $1.99 844,444 0.8 844,444 $2.00 - $2.99 75,000 4.6 75,000 $3.00 - $3.99 70,000 4.3 70,000 $4.00 - $4.99 2,159,635 2.2 2,159,635 $5.00 - $5.99 195,989 2.2 195,989 $6.00 - $7.99 40,000 1.3 40,000 $8.00 - $9.99 2,500 0.7 2,500 $10.00 - $14.99 40,400 1.0 40,400 $15.00 - $19.99 33,873 0.4 33,873 4,601,841 2.2 4,601,841
Schedule of Stock Option by Exercise Price	The following table presents information related to stock options at March 31, 2019: Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $0.75 - $0.99 4,631,700 7.1 2,838,709 $1.00 - $5.99 46,668 1.0 46,668 $6.00 - $19.99 37,500 4.8 37,500 $20.00 - $30.00 35,000 3.0 35,000 4,750,868 6.9 2,957,877
Schedule of Stock Option Expense	The following table presents information related to stock option expense: Weighted Average For the Three Months Ended Unrecognized at Remaining Amortization March 31, March 31, Period 2019 2018 2019 (Years) Consulting $ 296,081 $ 264,227 $ 356,980 0.4 Research and development 149,794 75,845 494,727 1.3 General and administrative 283,802 494,548 819,204 0.8 $ 729,677 $ 834,620 $ 1,670,911 0.9

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	3 Months Ended
	Mar. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Changes in Fair Value of Level 3 Derivative Liabilities	The following table sets forth a summary of the changes in the fair value of Level 3 derivative liabilities that are measured at fair value on a recurring basis: Beginning balance as of January 1, 2019 $ 1,094,607 Issuance of derivative liabilities 2,972,400 Extinguishment of derivative liabilities in connection with convertible note repayments and exchanges (844,124 ) Change in fair value of derivative liabilities 46,264 Reclassification of derivative liabilities to equity (2,517,254 ) Ending balance as of March 31, 2019 $ 751,893
Summary of Derivative Liabilities Fair Value Assumption	In applying the Multinomial Lattice and Black-Scholes option pricing models to derivatives issued and outstanding during the three months ended March 31, 2019 and 2018, the Company used the following assumptions: For the Three Months Ended March 31, 2019 2018 Risk free interest rate 2.21% - 2.62 % 1.22% - 2.56 % Expected term (years) 0.07 - 5.00 0.75 - 4.66 Expected volatility 104% - 156 % 100% - 111 % Expected dividends 0.00 % 0.00 %

Going Concern and Management'_2

Going Concern and Management's Plans (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Working capital deficiency	$ 8,081,062
Stockholder's deficiency	7,652,744	$ 7,690,296	$ 8,641,038	$ 6,836,568
Net loss	3,883,172	$ 2,507,660
Note payable past due	190,028
Subsequent to March 31, 2019 [Member]
Proceeds from equity financings	556,000
Proceeds from debt financings	728,280
Exchanges for equity	528,028
Repayments of debt	$ 573,400

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Accounting Policies [Abstract]
Royalty revenue	$ 29,000	$ 19,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Weighted Average Dilutive Common Shares (Details) - shares	3 Months Ended
	Mar. 31, 2019		Mar. 31, 2018
Total potentially dilutive shares	20,100,180		7,791,372
Options [Member]
Total potentially dilutive shares	4,750,868		3,615,369
Warrants [Member]
Total potentially dilutive shares	4,601,841		3,311,005
Convertible Notes [Member]
Total potentially dilutive shares	10,747,471	[1]	864,998
[1]	As of March 31, 2019, many of the convertible notes had variable conversion prices and the shares were estimated based on market conditions. Pursuant to the note agreements, there were 56,462,559 shares of common stock reserved for future note conversions.

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Weighted Average Dilutive Common Shares (Details) (Parenthetical)	Mar. 31, 2019shares
Accounting Policies [Abstract]
Common stock, reserved for future issuance	56,462,559

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Gain (loss) on settlement of notes payable, net	$ 448,486	$ 18,837
Exchange Agreement [Member] | Consultant [Member]
Accrued consulting fees	$ 46,500
Stock issued in exchange of consulting fees	10,000
Payment of consulting fees	$ 10,000
Common stock aggregate grant date value	7,200
Gain (loss) on settlement of notes payable, net	$ 29,300

Accrued Expenses and Other Cu_4

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Accrued Expenses and Other Current Liabilities [Line Items]
Less: accrued expenses, current portion	$ 2,493,867	$ 2,302,176
Accrued expenses, non-current portion		36,500
Accrued Expenses and Other Current Liabilities [Member]
Accrued Expenses and Other Current Liabilities [Line Items]
Accrued payroll and other accrued expenses	38,934	91,560
Accrued research and development expenses	676,175	646,175
Accrued general and administrative expenses	1,268,499	1,084,831
Accrued director compensation	482,500	482,500
Deferred rent	27,759	33,610
Total accrued expenses	2,493,867	2,338,676
Less: accrued expenses, current portion	2,493,867	2,302,176
Accrued expenses, non-current portion		$ 36,500

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2019		Mar. 31, 2018	Dec. 31, 2018
Debt Instrument [Line Items]
Payment of notes payable	$ 1,315,000		$ 119,583
Notes payable	4,001,117	[1]		$ 4,149,553
Original issuance debt discount	$ 2,440,769			$ 936,866
Common stock, shares issued	14,732,411			11,728,394
Debt instrument principal conversion values			52,904
Loss on extinguishment of notes payable	$ (448,486)		$ (18,837)
Extinguished debt	141,818
Subsequent to March 31, 2019 [Member]
Debt Instrument [Line Items]
Convertible notes payable aggregate principal amount	$ 1,805,000
Debt instrument convertible conversion ratio	0.58
Related Party Notes [Member]
Debt Instrument [Line Items]
Debt principal amount	$ 127,742
Payment of notes payable	15,000
Convertible notes payable aggregate principal amount	$ 475,000
Debt instrument, convertible, conversion price	$ 0.60
Warrant term	5 years
Warrant exercise price	$ 0.80
Loss on extinguishment of notes payable	$ 121,805
Repayments of debt	1,300,000
Related Party Notes [Member] | Extended Maturity Date from January 2019 to December 2019 [Member]
Debt Instrument [Line Items]
Notes payable	30,000
Related Party Notes [Member] | Scientific Advisory Board Member [Member]
Debt Instrument [Line Items]
Debt principal amount	$ 475,000
Interest rate	15.00%
Debt maturity period	maturity dates between July 2019 and August 2019.
Other Related Party Notes [Member]
Debt Instrument [Line Items]
Notes payable	$ 705,000
Convertible Notes [Member]
Debt Instrument [Line Items]
Debt maturity period	Original maturity dates ranging between July 2019 and March 2020.
Convertible notes payable aggregate principal amount	$ 2,755,000
Warrant term	5 years
Warrant exercise price	$ 1
Proceeds from convertible debt	$ 2,598,918
Original issuance debt discount	$ 156,083
Common stock, shares issued	40,000
Fair value of warrant	$ 24,000
Convertible debt fair value	148,014
Debt instrument principal conversion values	1,510,282
Loss on extinguishment of notes payable	235,687
Repayments of debt	76,169
Aggregate principal on prepayment premiums	184,637
Extinguishments of debt discounts	$ 51,050
Convertible Notes [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	8.00%
Convertible Notes [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	15.00%
Embedded Conversion Options and Note Provisions [Member]
Debt Instrument [Line Items]
Convertible notes payable aggregate principal amount	$ 3,465,780
Warrant exercise price	$ 0.80
Debt instrument principal conversion values	$ 1,890,000
Embedded Conversion Options and Note Provisions [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price	$ 1
Debt instrument convertible conversion ratio	0.58
Embedded Conversion Options and Note Provisions [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price	$ 2
Debt instrument convertible conversion ratio	0.65
Embedded Conversion Options and Note Provisions 1 [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price	$ 2.15
Debt instrument principal conversion values	$ 50,000
Embedded Conversion Options and Note Provisions 2 [Member]
Debt Instrument [Line Items]
Debt instrument principal conversion values	$ 875,780
Embedded Conversion Options and Note Provisions 2 [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument convertible conversion ratio	0.58
Embedded Conversion Options and Note Provisions 2 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument convertible conversion ratio	0.65
Embedded Conversion Options and Note Provisions 3 [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price	$ 0.60
Debt instrument principal conversion values	$ 650,000
MPO [Member]
Debt Instrument [Line Items]
Convertible notes payable aggregate principal amount	$ 55,000
Percentage on prepayment premium	35.00%
Prepays 1 [Member]
Debt Instrument [Line Items]
Convertible notes payable aggregate principal amount	$ 3,953,014
Percentage on prepayment premium	30.00%
Prepays 2 [Member]
Debt Instrument [Line Items]
Percentage on prepayment premium	40.00%
MFN [Member]
Debt Instrument [Line Items]
Convertible notes payable aggregate principal amount	$ 2,052,742
MFN [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument convertible conversion ratio	0.58
MFN [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument convertible conversion ratio	0.65
ECO [Member]
Debt Instrument [Line Items]
Debt principal amount	$ 148,014
Original issuance debt discount	2,307,602
Convertible debt fair value	84,798
Debt instrument principal conversion values	2,392,400
Loss on extinguishment of notes payable	84,798
Derivative liability	84,798
Conversions, Exchanges and Other [Member]
Debt Instrument [Line Items]
Debt principal amount	641,649
Proceeds from convertible debt	1,510,282
Original issuance debt discount	$ 121,804
Common stock, shares issued	1,984,017
Debt instrument principal conversion values	$ 1,388,477
Loss on extinguishment of notes payable	121,805
Accrued interest	24,509
Derivative liability	844,123
Amount of outstanding principal related party past maturity	148,014
Accrued interest reclassified to principal	23,013
Extinguished debt	141,818
Conversions, Exchanges and Other [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price				$ 0.28
Conversions, Exchanges and Other [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price				$ 0.42
New Convertible Note [Member]
Debt Instrument [Line Items]
Debt principal amount	$ 148,014
Debt maturity period	Maturity date in March 2020
Debt instrument interest rate	12.00%
Loss on extinguishment of notes payable	$ 90,994
Debt conversion fair value percentage	10.00%
Other Notes [Member]
Debt Instrument [Line Items]
Debt principal amount	$ 7,500
Debt maturity period	Maturity date in January 2019 to a new maturity date in December 2019.
Convertible Notes [Member]
Debt Instrument [Line Items]
Debt principal amount	$ 148,014
Original issuance debt discount	$ 7,052
Common stock, shares issued	10,000
Derivative liability	$ 2,392,400
[1]	As of March 31, 2019, outstanding related party notes, convertible notes and other notes in the aggregate principal amount of $0, $127,742 and $7,500, respectively, were considered past due.

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable Activity (Details) - USD ($)		3 Months Ended
		Mar. 31, 2019	Mar. 31, 2018
Outstanding beginning		$ 4,149,553
Issuances		3,378,014
Exchanges for equity		(519,845)
Repayments		(1,315,000)	$ (119,583)
Extinguishment of notes payable		(141,818)
Recognition of debt discount		(2,494,735)
Accretion of interest expense		127,743	67,562
Accrued interest reclassified to notes payable principal		23,013
Amortization of debt discount		743,142	$ 261,646
Outstanding ending	[1]	4,001,117
Convertible Notes [Member]
Outstanding beginning		4,309,415
Issuances	[2]	2,903,014
Exchanges for equity		(641,649)
Repayments		(1,300,000)
Extinguishment of notes payable
Recognition of debt discount
Accretion of interest expense
Accrued interest reclassified to notes payable principal
Amortization of debt discount
Outstanding ending	[1],[3]	5,270,780
Other Notes [Member]
Outstanding beginning		132,501
Issuances
Exchanges for equity
Repayments
Extinguishment of notes payable	[2]	(148,014)
Recognition of debt discount
Accretion of interest expense
Accrued interest reclassified to notes payable principal		23,013
Amortization of debt discount
Outstanding ending	[1]	7,500
Debt Discount [Member]
Outstanding beginning		(1,012,363)
Issuances
Exchanges for equity		121,804
Repayments		51,050
Extinguishment of notes payable		6,196
Recognition of debt discount		(2,494,735)
Accretion of interest expense		127,743
Accrued interest reclassified to notes payable principal
Amortization of debt discount		743,142
Outstanding ending	[1]	(2,457,163)
Related Party Notes [Member]
Outstanding beginning		720,000
Issuances		475,000
Exchanges for equity
Repayments		(15,000)
Extinguishment of notes payable
Recognition of debt discount
Accretion of interest expense
Accrued interest reclassified to notes payable principal
Amortization of debt discount
Outstanding ending	[1]	$ 1,180,000
[1]	As of March 31, 2019, outstanding related party notes, convertible notes and other notes in the aggregate principal amount of $0, $127,742 and $7,500, respectively, were considered past due.
[2]	During the three months ended March 31, 2019, a convertible note in the principal amount of $148,014 was issued concurrently with the extinguishment of a certain note payable in the same aggregate principal amount. See below within Note 5 - Notes Payable - Conversions, Exchanges and Other for additional details.
[3]	As of March 31, 2019, a portion of convertible notes with an aggregate principal balance of $3,465,780 were convertible into shares of common stock at the election of the holder any time until the balance has been paid in full. As of March 31, 2019, a portion of convertible notes with an aggregate principal balance of $1,805,000, which are not currently convertible, will become convertible into shares of the Company's common stock at the election of the respective holder subsequent to March 31, 2019.

Notes Payable - Schedule of N_2

Notes Payable - Schedule of Notes Payable Activity (Details) (Parenthetical) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Debt conversion, converted instrument, amount		$ 52,904
Convertible Notes [Member]
Debt instrument, face amount	$ 0
Related Party Notes [Member]
Debt instrument, face amount	127,742
Other Notes [Member]
Debt instrument, face amount	7,500
Convertible Notes [Member]
Debt instrument, face amount	148,014
Debt conversion, converted instrument, amount	1,805,000
Convertible notes with a principal balance	$ 3,465,780

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Jan. 31, 2019	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Warrant term		2 years 2 months 12 days
Warrants to purchase common stock		4,601,841
Rent expense		$ 30,000	$ 31,000
Employment Agreement [Member]
Accrued bonuses		9,000		$ 91,000
Business Advisory Services [Member] | Consulting Agreements [Member]
Consulting agreements expires date	Dec. 31, 2019
Consulting agreements,description	An agreement for business advisory services that had expired on December 31, 2018 was further extended and now provides for an expiration date of December 31, 2019
Warrant term	5 years
Warrants to purchase common stock	100,000
Exercise price per share	$ 1
Fair value of aggregate of warrant	$ 56,000
Employment Agreements [Member] | 2019 Bonus [Member]
Accrued bonuses		$ 30,305

Stockholders' Deficiency (Detai

Stockholders' Deficiency (Details Narrative) - USD ($)	Mar. 25, 2019	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Common stock, shares authorized		75,000,000		75,000,000
Warrants to purchase common stock		4,601,841
Warrant term		2 years 2 months 12 days
Stock based compensation expenses		$ 785,678	$ 882,812
Warrants [Member]
Weighted average estimated fair value of warrants granted per share		$ 0.51	$ 1.22
Stock Option [Member]
Number of option to purchase shares		4,631,700
Exercise prices of stock options		$ 0.75
Incremental value of modified stock options		$ 452,637
Stock Warrants [Member]
Stock based compensation expenses		56,000	$ 48,192
Unrecognized stock-based compensation expense
Common Stock and Warrant Offering [Member]
Warrants to purchase common stock		1,000,000
Aggregate gross proceeds of warrants		$ 600,000
Fair value adjustment of warrants		$ 500,000
Common Stock and Warrant Offering [Member] | Five-Year Immediately Vested [Member]
Warrants to purchase common stock		500,000
Warrant term		5 years
Exercise price per share		$ 0.85
Common Stock and Warrant Offering [Member] | One-Year Immediately Vested [Member]
Warrants to purchase common stock		500,000
Warrant term		1 year
Exercise price per share		$ 0.70
Maximum [Member] | Stock Option [Member]
Exercise prices of stock options		4.70
Minimum [Member] | Stock Option [Member]
Exercise prices of stock options		$ 1
Board of Directors [Member]
Reverse split, description	Effect a reverse split of the Company's common stock at a ratio of not less than 1-for-2 and not more than 1-for-20, with the Board of Directors having the discretion as to whether or not the reverse stock split is to be effected, and with the exact ratio of any reverse stock split to be set at a whole number within the above range as determined by the Board of Directors in its discretion.
Board of Directors [Member] | 2010 Equity Participation Plan [Member]
Common stock, shares authorized	20,000,000
Board of Directors [Member] | Maximum [Member]
Common stock, shares authorized	150,000,000

Stockholders' Deficiency - Sche

Stockholders' Deficiency - Schedule of Share Based Payment Award Stock Warrants Valuation Assumptions (Details) - Warrant [Member]	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Expected dividends	0.00%	0.00%
Minimum [Member]
Risk free interest rate	2.47%	1.92%
Contractual term (years)	1 year	1 year 11 months 23 days
Expected volatility	140.00%	128.00%
Maximum [Member]
Risk free interest rate	2.62%	2.29%
Contractual term (years)	5 years	5 years
Expected volatility	150.00%	129.00%

Stockholders' Deficiency - Sc_2

Stockholders' Deficiency - Schedule of Warrant Activity (Details)	3 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
Number of Warrants Exercisable, Balance	2,957,877
Warrant [Member]
Number of Warrants Outstanding, Beginning Balance	3,483,403
Number of Warrants Outstanding, Issued	1,140,000
Number of Warrants Outstanding, Expired	(21,562)
Number of Warrants Outstanding, Ending Balance	4,601,841
Number of Warrants Exercisable, Balance	4,601,841
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 3.63
Weighted Average Exercise Price Outstanding, Issued | $ / shares	0.80
Weighted Average Exercise Price Outstanding, Expired | $ / shares	4.80
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	2.92
Weighted Average Exercise Price Exercisable, Balance | $ / shares	$ 2.92
Weighted Average Remaining Life In Years Outstanding	2 years 2 months 12 days
Weighted Average Remaining Life In Years Exercisable	2 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding | $	$ 45,000
Aggregate Intrinsic Value, Exercisable | $	$ 45,000

Stockholders' Deficiency - Sc_3

Stockholders' Deficiency - Schedule of Stock Warrant (Details)	Mar. 31, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	4,601,841
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 2 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	4,601,841
Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	1,140,000
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 1 month 6 days
Warrants Exercisable, Exercisable Number of Warrants	1,140,000
Exercise Price One [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 0.70
Exercise Price One [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 0.99
Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	844,444
Warrants Exercisable, Weighted Average Remaining Life In Years	9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	844,444
Exercise Price Two [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 1
Exercise Price Two [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 1.99
Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	75,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 7 months 6 days
Warrants Exercisable, Exercisable Number of Warrants	75,000
Exercise Price Three [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 2
Exercise Price Three [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 2.99
Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	70,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 3 months 19 days
Warrants Exercisable, Exercisable Number of Warrants	70,000
Exercise Price Four [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 3
Exercise Price Four [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 3.99
Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	2,159,635
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 2 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	2,159,635
Exercise Price Five [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 4
Exercise Price Five [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 4.99
Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	195,989
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 2 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	195,989
Exercise Price Six [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 5
Exercise Price Six [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 5.99
Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	40,000
Warrants Exercisable, Weighted Average Remaining Life In Years	1 year 3 months 19 days
Warrants Exercisable, Exercisable Number of Warrants	40,000
Exercise Price Seven [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 6
Exercise Price Seven [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 7.99
Exercise Price Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	2,500
Warrants Exercisable, Weighted Average Remaining Life In Years	8 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	2,500
Exercise Price Eight [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 8
Exercise Price Eight [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 9.99
Exercise Price Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	40,400
Warrants Exercisable, Weighted Average Remaining Life In Years	1 year
Warrants Exercisable, Exercisable Number of Warrants	40,400
Exercise Price Nine [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 10
Exercise Price Nine [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 14.99
Exercise Price Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	33,873
Warrants Exercisable, Weighted Average Remaining Life In Years	4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	33,873
Exercise Price Nine [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 15
Exercise Price Nine [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 19.99

Stockholders' Deficiency - Sc_4

Stockholders' Deficiency - Schedule of Stock Option by Exercise Price (Details)	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	4,750,868
Options Exercisable, Weighted Average Remaining Life In Years	6 years 10 months 25 days
Options Exercisable, Exercisable Number of Options	2,957,877
Exercise Price One [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower | $ / shares	$ 0.75
Options Outstanding, Exercise Price, Upper | $ / shares	$ 0.99
Options Outstanding, Outstanding Number of Options	4,631,700
Options Exercisable, Weighted Average Remaining Life In Years	7 years 1 month 6 days
Options Exercisable, Exercisable Number of Options	2,838,709
Exercise Price Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower | $ / shares	$ 1
Options Outstanding, Exercise Price, Upper | $ / shares	$ 5.99
Options Outstanding, Outstanding Number of Options	46,668
Options Exercisable, Weighted Average Remaining Life In Years	1 year
Options Exercisable, Exercisable Number of Options	46,668
Exercise Price Three [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower | $ / shares	$ 6
Options Outstanding, Exercise Price, Upper | $ / shares	$ 19.99
Options Outstanding, Outstanding Number of Options	37,500
Options Exercisable, Weighted Average Remaining Life In Years	4 years 9 months 18 days
Options Exercisable, Exercisable Number of Options	37,500
Exercise Price Four [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower | $ / shares	$ 20
Options Outstanding, Exercise Price, Upper | $ / shares	$ 30
Options Outstanding, Outstanding Number of Options	35,000
Options Exercisable, Weighted Average Remaining Life In Years	3 years
Options Exercisable, Exercisable Number of Options	35,000

Stockholders' Deficiency - Sc_5

Stockholders' Deficiency - Schedule of Stock Option Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Options [Member]
Stock-based compensation expense		$ 834,620
Unrecognized expense	$ 1,670,911
Weighted Average Remaining Amortization Period		10 months 25 days
Option [Member]
Stock-based compensation expense	$ 729,677
Weighted Average Remaining Amortization Period	10 months 25 days
Consulting Expenses [Member] | Options [Member]
Stock-based compensation expense	$ 296,081
Unrecognized expense	$ 356,980
Weighted Average Remaining Amortization Period	4 months 24 days
Research and Development Expense [Member] | Options [Member]
Stock-based compensation expense	$ 149,794	$ 75,845
Unrecognized expense	$ 494,727
Weighted Average Remaining Amortization Period	1 year 3 months 19 days	1 year 3 months 19 days
General and Administrative Expense [Member] | Options [Member]
Stock-based compensation expense	$ 283,802	$ 494,548
Unrecognized expense	$ 819,204
Weighted Average Remaining Amortization Period	9 months 18 days	9 months 18 days
Consulting Expense [Member] | Options [Member]
Stock-based compensation expense		$ 264,227
Weighted Average Remaining Amortization Period		4 months 24 days

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Extinguishment of derivative liabilities in connection with convertible note repayments, conversions and exchanges	$ 844,124
Reclassification of derivative liabilities to equity	2,517,254	$ 9,397
Gain on derivative liabilities	46,264
Warrants [Member]
Fair value of derivative liabilities	27,260
Gain on derivative liabilities			$ 50,574
Embedded Conversion Options [Member]
Fair value of derivative liabilities	724,634
Gain on derivative liabilities	96,838
Warrant [Member]
Derivative liabilities	580,000
Convertible Notes [Member]
Derivative liabilities	$ 2,392,400

Derivative Liabilities - Summar

Derivative Liabilities - Summary of Changes in Fair Value of Level 3 Derivative Liabilities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative liabilities, beginning balance	$ 1,094,607
Issuance of derivative liabilities	2,972,400
Extinguishment of derivative liabilities in connection with convertible note repayments, conversions and exchanges	(844,124)
Change in fair value of derivative liabilities	46,264
Reclassification of derivative liabilities to equity	(2,517,254)	$ (9,397)
Derivative liabilities, ending balance	$ 751,893

Derivative Liabilities - Summ_2

Derivative Liabilities - Summary of Derivative Liabilities Fair Value Assumption (Details) - Valuation Technique, Option Pricing Model [Member]	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Risk Free Interest Rate [Member] | Minimum [Member]
Derivatives, fair value measurement input, percentages	0.0221	0.0122
Risk Free Interest Rate [Member] | Maximum [Member]
Derivatives, fair value measurement input, percentages	0.0262	0.0256
Expected Term [Member] | Minimum [Member]
Derivatives, fair value measurement input, term	26 days	9 months
Expected Term [Member] | Maximum [Member]
Derivatives, fair value measurement input, term	5 years	4 years 7 months 28 days
Expected Volatility [Member] | Minimum [Member]
Derivatives, fair value measurement input, percentages	1.04	1
Expected Volatility [Member] | Maximum [Member]
Derivatives, fair value measurement input, percentages	1.56	1.11
Expected Dividend Rate [Member]
Derivatives, fair value measurement input, percentages	0	0

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	May 15, 2019	Mar. 31, 2019	Mar. 31, 2018	Apr. 15, 2019
Warrant term		2 years 2 months 12 days
Warrants to purchase common stock		4,601,841
Repayments of convertible notes payable		$ 1,315,000	$ 119,583
Subsequent Event [Member] | Lenders [Member]
Aggragate principal amount	$ 504,501
Accrued interest	$ 23,527
Debt instrument principal conversion share	1,488,673
Subsequent Event [Member] | Lenders [Member] | Minimum [Member]
Debt instrument conversion price	$ 0.20
Subsequent Event [Member] | Lenders [Member] | Maximum [Member]
Debt instrument conversion price	$ 0.43
Subsequent Event [Member] | Convertible Promissory Notes [Member]
Accrued interest	$ 29,371
Repayments of convertible notes payable	501,629
Aggregate principal on prepayment premiums	42,400
Subsequent Event [Member] | Convertible Promissory Notes [Member] | Lenders [Member]
Aggregate principal amount of convertible notes payable	760,000
Proceeds from issuance of convertible notes	$ 728,280
Convertible notes bear interest rate	12.00%
Debt maturity date, description	Original maturity dates ranging from October 2019 to January 2020
Debt instrument conversion rate	58.00%
Common stock issued in connection with debt issuance	68,873
Percentage on prepayment premium	25.00%
Subsequent Event [Member] | Second Ninety Day [Member] | Convertible Promissory Notes [Member] | Lenders [Member]
Percentage on prepayment premium	35.00%
Subsequent Event [Member] | Common Stock and Warrant Offerings [Member]
Warrant term	5 years
Warrants to purchase common stock	80,000
Exercise price per share	$ 1
Subsequent Event [Member] | Common Stock and Warrant Offerings [Member] | One-Year Immediately Vested [Member]
Warrant term	5 years
Warrants to purchase common stock	555,556
Exercise price per share	$ 0.85
Subsequent Event [Member] | Common Stock and Warrant Offerings [Member] | Five-Year Immediately Vested [Member]
Warrant term	1 year
Warrants to purchase common stock	555,555
Exercise price per share	$ 0.70
Subsequent Event [Member] | Common Stock and Warrant Offerings [Member] | Scientific Advisory Board Member [Member]
Number of common stock shares issued	80,000
Stock issued during price per shares	$ 0.70
Subsequent Event [Member] | Common Stock and Warrant Offerings [Member] | Certain Related Party [Member]
Number of common stock shares issued	1,111,111
Stock issued during price per shares				$ 0.45